- Home
- HSBC vs AZN Comparison
HSBC vs AZN Comparison
Compare HSBC & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HSBC | AZN |
|---|---|---|
| Founded | 1865 | 1992 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 304.0B | 285.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HSBC | AZN |
|---|---|---|
| Price | $84.04 | $194.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 2.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.35% | 1.62% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.21 | $9.84 |
| Revenue Next Year | $3.61 | $6.16 |
| P/E Ratio | $94.79 | ★ $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.66 | $61.24 |
| 52 Week High | $94.80 | $212.71 |
Technical Indicators
Market Signals| Indicator | HSBC | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 42.89 | 61.35 |
| Support Level | $83.93 | $89.28 |
| Resistance Level | $90.81 | $211.32 |
| Average True Range (ATR) | 1.61 | 3.26 |
| MACD | -0.86 | -5.05 |
| Stochastic Oscillator | 10.53 | 7.77 |
Price Performance
Historical ComparisonAbout HSBC HSBC Holdings plc.
Established in 1865 in Hong Kong, London-based HSBC is one of the largest banks in the world, with assets of USD 3 trillion and over 40 million customers worldwide. It operates in more than 50 countries with more than 200,000 full-time staff. The United Kingdom and Hong Kong are its two largest markets. The bank offers retail, commercial and institutional banking, global banking and markets, wealth management, and private banking.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.